Inovio Pharmaceuticals to price public offering of common-share units

Proceeds fund general corporate purposes, including clinical trials

By Devika Patel

Knoxville, Tenn., Nov. 30 - Inovio Pharmaceuticals, Inc. will price a public offering of units, according to a prospectus supplement filed Wednesday with the Securities and Exchange Commission.

The company will sell units of one common share and 0.75 five-year warrants.

Brean Murray, Carret & Co. is the underwriter and will also have a 45-day over-allotment option.

Proceeds will be used for general corporate purposes, including clinical trials, research and development, general and administrative expenses, manufacturing expenses and potential acquisitions.

Inovio is a San Diego vaccine manufacturer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.